DTCFF Stock Chart & Stats
$0.29
$0.02(8.55%)
At close: 4:00 PM EDT
$0.29
$0.02(8.55%)
Day’s Range― - ―
52-Week Range$0.25 - $0.78
Previous CloseN/A
Volume10.41K
Average Volume (3M)599.00
Market Cap
$21.08M
Enterprise Value$31.08
Total Cash (Recent Filing)$2.95M
Total Debt (Recent Filing)$1.56M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe Accum® intracellular-delivery platform is a structural competitive asset: platform technologies can be applied across multiple indications, enabling pipeline leverage, partnership potential and repeatable R&D efficiencies that support durable long-term value if clinical progress continues.
Improved Loss Trajectory (2024→2025)A material reduction in annual net losses from 2024 to 2025 indicates management can materially cut spend or reprioritize programs. If sustained, this structural improvement reduces frequency of financing, extends runway and shows operational discipline important for development-stage biotech durability.
Balance Sheet BufferPositive TTM equity and rising total assets provide a meaningful cushion versus prior periods. This improved balance-sheet position increases resilience to short-term shocks, supports ongoing R&D investment and improves credibility with partners and capital providers if cash burn is managed.
Bears Say
No Revenue / Development-stage RiskThe company reports no product revenue, leaving operations fully dependent on development milestones and external funding. This structural absence of recurring sales concentrates risk in binary clinical/regulatory outcomes and makes long-term sustainability contingent on successful program commercialization or persistent financing.
Persistent Negative Cash FlowConsistent negative operating and free cash flows create a structural funding requirement. Ongoing cash burn forces repeated capital raises or strategic partnerships, which can dilute shareholders, constrain R&D sequencing, and limit the firm's ability to sustain multi-year development programs without external financing.
Financing / Dilution Risk From Past Negative EquityHistoric negative equity and existing debt signal prior recapitalizations and limited financial flexibility. With ongoing losses, the company faces elevated probability of further capital raises, which raises dilution risk and could pressure governance and strategic choices over the medium term.
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.25 and its highest was $0.78 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $21.08M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 87 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―